16 October 2014 - The Canadian Drug Expert Committee (CDEC) has recommended that stiripentol be listed for use in combination with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (Dravet syndrome), whose seizures are not adequately controlled with clobazam and valproate alone, if the following conditions are met: 

• The patient is under the care of a neurologist. 
• Reduction in price to improve the cost-effectiveness to an acceptable level.

For more details, go to: http://www.cadth.ca/media/cdr/complete/cdr_complete_Diacomit_October_20_2014.pdf